zonisamide has been researched along with Lewy Body Disease in 13 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
Lewy Body Disease: A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zonisamide is an anti-epileptic medication with multiple mechanisms of action and a favorable safety profile." | 6.72 | The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data. ( Leverenz, JB; Tousi, B, 2021) |
| " No unexpected neurological or psychiatric adverse events occurred, and no adverse events increased in incidence in the open-label period." | 3.11 | Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial. ( Hasegawa, K; Kajiwara, R; Kosaka, K; Murata, M; Odawara, T; Tagawa, M; Takeuchi, H, 2022) |
| " Other outcomes included the changes in Mini-Mental State Examination (MMSE) and Neuropsychiatric Inventory-10 (NPI-10) scores, and the incidence of adverse events." | 3.01 | Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials. ( Hasegawa, K; Kochi, K; Konishi, O; Maruyama, H; Odawara, T; Toya, S, 2021) |
| "Zonisamide appears to be a new treatment option for patients with PD and DLB." | 2.82 | Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review. ( Jiang, Z; Kong, L; Liu, H; Wang, Z; Xi, J; Yu, X, 2022) |
| "Zonisamide is an anti-epileptic medication with multiple mechanisms of action and a favorable safety profile." | 2.72 | The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data. ( Leverenz, JB; Tousi, B, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 8 (61.54) | 2.80 |
| Authors | Studies |
|---|---|
| Kong, L | 1 |
| Xi, J | 1 |
| Jiang, Z | 1 |
| Yu, X | 1 |
| Liu, H | 1 |
| Wang, Z | 1 |
| Ikeda, M | 1 |
| Mori, E | 1 |
| Orimo, S | 1 |
| Yamada, T | 1 |
| Konishi, O | 2 |
| Murata, M | 3 |
| Odawara, T | 5 |
| Hasegawa, K | 4 |
| Kajiwara, R | 2 |
| Takeuchi, H | 2 |
| Tagawa, M | 3 |
| Kosaka, K | 3 |
| Panza, F | 1 |
| Lozupone, M | 1 |
| Watling, M | 1 |
| Imbimbo, BP | 1 |
| Kochi, K | 1 |
| Maruyama, H | 1 |
| Toya, S | 1 |
| Tousi, B | 1 |
| Leverenz, JB | 1 |
| Hinkle, JT | 1 |
| Pontone, GM | 1 |
| Hershey, LA | 2 |
| Irwin, DJ | 1 |
| Iiyama, S | 1 |
| Nakamura, M | 1 |
| Coleman-Jackson, R | 1 |
| Shiozaki, K | 1 |
| Togo, T | 1 |
| Hirayasu, Y | 1 |
| Sato, S | 1 |
| Mizukami, K | 1 |
| Asada, T | 1 |
3 reviews available for zonisamide and Lewy Body Disease
| Article | Year |
|---|---|
Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review.
Topics: Contusions; Humans; Lewy Body Disease; Parkinson Disease; Sleepiness; Zonisamide | 2022 |
The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data.
Topics: Clinical Trials, Phase III as Topic; Dementia; Humans; Lewy Body Disease; Zonisamide | 2021 |
Pharmacological Management of Dementia with Lewy Bodies.
Topics: Age Factors; Aged; Anticonvulsants; Antiparkinson Agents; Cholinesterase Inhibitors; Clinical Trials | 2019 |
5 trials available for zonisamide and Lewy Body Disease
| Article | Year |
|---|---|
Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study.
Topics: Humans; Levodopa; Lewy Body Disease; Zonisamide | 2023 |
Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial.
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Double-Blind Method; Dyskinesias; Female; Humans; | 2020 |
Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials.
Topics: Aged; Anticonvulsants; Double-Blind Method; Female; Humans; Japan; Lewy Body Disease; Male; Neuropsy | 2021 |
Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial.
Topics: Double-Blind Method; Humans; Lewy Body Disease; Outpatients; Parkinsonian Disorders; Treatment Outco | 2022 |
Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Double-Blind Method; Drug Therapy, Combination; Femal | 2018 |
5 other studies available for zonisamide and Lewy Body Disease
| Article | Year |
|---|---|
Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism.
Topics: Brain; Europe; Humans; Levodopa; Lewy Body Disease; Zonisamide | 2021 |
Invited Perspective on the "Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial".
Topics: Double-Blind Method; Humans; Lewy Body Disease; Parkinsonian Disorders; Zonisamide | 2022 |
Zonisamide for DLB parkinsonism: An old drug used in a new context.
Topics: Double-Blind Method; Humans; Levodopa; Lewy Body Disease; Parkinsonian Disorders; Zonisamide | 2018 |
Administration of zonisamide in three cases of dementia with Lewy bodies.
Topics: Aged; Antiparkinson Agents; Caregivers; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 2010 |
Successful treatment of extrapyramidal and psychotic symptoms with zonisamide in a patient with dementia with Lewy bodies.
Topics: Aged; Basal Ganglia Diseases; Female; Humans; Isoxazoles; Lewy Body Disease; Psychotic Disorders; Tr | 2010 |